554 related articles for article (PubMed ID: 25322077)
1. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
[TBL] [Abstract][Full Text] [Related]
2. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging.
Russell DS; Jennings DL; Barret O; Tamagnan GD; Carroll VM; Caillé F; Alagille D; Morley TJ; Papin C; Seibyl JP; Marek KL
Neurology; 2016 Feb; 86(8):748-54. PubMed ID: 26802091
[TBL] [Abstract][Full Text] [Related]
3. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
[TBL] [Abstract][Full Text] [Related]
4. In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654.
Barret O; Thomae D; Tavares A; Alagille D; Papin C; Waterhouse R; McCarthy T; Jennings D; Marek K; Russell D; Seibyl J; Tamagnan G
J Nucl Med; 2014 Aug; 55(8):1297-304. PubMed ID: 24898025
[TBL] [Abstract][Full Text] [Related]
5. MR-based spatial normalization improves [18F]MNI-659 PET regional quantification and detectability of disease effect in the Q175 mouse model of Huntington's disease.
Bertoglio D; Verhaeghe J; Kosten L; Thomae D; Van der Linden A; Stroobants S; Wityak J; Dominguez C; Mrzljak L; Staelens S
PLoS One; 2018; 13(10):e0206613. PubMed ID: 30365550
[TBL] [Abstract][Full Text] [Related]
6. In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [
Svedberg MM; Varnäs K; Varrone A; Mitsios N; Mulder J; Gulyás B; Beaumont V; Munoz-Sanjuan I; Zaleska MM; Schmidt CJ; Halldin C; Mrzljak L
Brain Res; 2019 May; 1711():140-145. PubMed ID: 30664847
[TBL] [Abstract][Full Text] [Related]
7. Differential Changes in Functional Connectivity of Striatum-Prefrontal and Striatum-Motor Circuits in Premanifest Huntington's Disease.
Kronenbuerger M; Hua J; Bang JYA; Ultz KE; Miao X; Zhang X; Pekar JJ; van Zijl PCM; Duan W; Margolis RL; Ross CA
Neurodegener Dis; 2019; 19(2):78-87. PubMed ID: 31412344
[TBL] [Abstract][Full Text] [Related]
8. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
Niccolini F; Haider S; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Piccini P; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
Brain; 2015 Oct; 138(Pt 10):3016-29. PubMed ID: 26198591
[TBL] [Abstract][Full Text] [Related]
9. PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression.
Fazio P; Fitzer-Attas CJ; Mrzljak L; Bronzova J; Nag S; Warner JH; Landwehrmeyer B; Al-Tawil N; Halldin C; Forsberg A; Ware J; Dilda V; Wood A; Sampaio C; Varrone A;
Mov Disord; 2020 Apr; 35(4):606-615. PubMed ID: 31967355
[TBL] [Abstract][Full Text] [Related]
10. Early grey matter changes in structural covariance networks in Huntington's disease.
Coppen EM; van der Grond J; Hafkemeijer A; Rombouts SA; Roos RA
Neuroimage Clin; 2016; 12():806-814. PubMed ID: 27830113
[TBL] [Abstract][Full Text] [Related]
11. Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies.
Niccolini F; Pagano G; Fusar-Poli P; Wood A; Mrzljak L; Sampaio C; Politis M
J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):185-196. PubMed ID: 28889093
[TBL] [Abstract][Full Text] [Related]
12. Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D
Fazio P; Schain M; Mrzljak L; Amini N; Nag S; Al-Tawil N; Fitzer-Attas CJ; Bronzova J; Landwehrmeyer B; Sampaio C; Halldin C; Varrone A
Neuroimage; 2017 May; 152():330-339. PubMed ID: 28254508
[TBL] [Abstract][Full Text] [Related]
13. Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers.
Wilson H; Niccolini F; Haider S; Marques TR; Pagano G; Coello C; Natesan S; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
J Neurol Sci; 2016 Sep; 368():243-8. PubMed ID: 27538642
[TBL] [Abstract][Full Text] [Related]
14. Huntington's Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers.
Cybulska K; Perk L; Booij J; Laverman P; Rijpkema M
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979301
[TBL] [Abstract][Full Text] [Related]
15. PET imaging shows loss of striatal PDE10A in patients with Huntington disease.
Ahmad R; Bourgeois S; Postnov A; Schmidt ME; Bormans G; Van Laere K; Vandenberghe W
Neurology; 2014 Jan; 82(3):279-81. PubMed ID: 24353339
[TBL] [Abstract][Full Text] [Related]
16. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
[TBL] [Abstract][Full Text] [Related]
17. Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of Huntington's disease.
Kuwert T; Noth J; Scholz D; Schwarz M; Lange HW; Töpper R; Herzog H; Aulich A; Feinendegen LE
Mov Disord; 1993; 8(1):98-106. PubMed ID: 8419813
[TBL] [Abstract][Full Text] [Related]
18. Does reduced [(123)I]-FP-CIT binding in Huntington's disease suggest pre-synaptic dopaminergic involvement?
Gamez J; Lorenzo-Bosquet C; Cuberas-Borrós G; Carmona F; Hernández-Vara J; Castilló J; Castell-Conesa J
Clin Neurol Neurosurg; 2010 Dec; 112(10):870-5. PubMed ID: 20724066
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
[TBL] [Abstract][Full Text] [Related]
20. Molecular Imaging in Huntington's Disease.
Wilson H; Politis M
Int Rev Neurobiol; 2018; 142():289-333. PubMed ID: 30409256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
